New York, New York–(Newsfile Corp. – October 29, 2021) – Pomerantz LLP is investigating claims on behalf of investors of Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

The investigation concerns whether Eyenovia and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On October 25, 2021, Eyenovia issued a press release “announc[ing] that MydCombi, the company’s proprietary, first-in-class combination microdose formulation of tropicamide and phenylephrine for in-office pupil dilation, has been reclassified as a drug-device combination product by the U.S. Food and Drug Administration in a Complete Response Letter for the company’s new drug application received on October 22, 2021.”

On this news, Eyenovia’s stock price fell sharply during intraday trading on October 25, 2021.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com

CONTACT:
Robert S. Willoughby
Pomerantz LLP
[email protected]
888-476-6529 ext. 7980

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/101399